secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2023-09-26T23:59:59+00:00
Accession:  0000950170-23-049796
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acasti Pharma closes $7.5M private placement for GTX-104 development
--------------------------------------------------------------------

- Closed private placement on Sept 25, 2023: 1.95M common shares at $1.848 each, pre-funded warrants for 2.11M shares, and common warrants for 2.54M shares at $3.003 exercise.
- Gross proceeds ~$7.5M, net ~$7.3M after fees; related parties (Shore Pharma, SS Pharma) participated.
- Proceeds intended for GTX-104 Phase 3 trial, pre-commercial planning, working capital, and general corporate purposes.
- Common warrants expire on the earlier of 60 days after FDA NDA acceptance for GTX-104 or 5 years from issuance.
- Company to file resale registration statement within 30 days; failure may trigger liquidated damages.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000095017023049796/0000950170-23-049796-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000095017023049796/acst-20230924.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-049796

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer